Knowledge Library

Hepatobiliary Disease Platform

The hepatobiliary system (comprised of the liver, gallbladder, and bile ducts) plays an important role in digestion and in the biotransformation and disposition of endogenous molecules and drugs. Hepatobiliary diseases range from minor infection or scarring to serious conditions such as cancer. At this year’s EASL conference, WuXi AppTec showcased our comprehensive platform of hepatobiliary-related …Read More >

Resource Type: Brochure
Resource Topic: in vivo Pharmacology, Liver Diseases, NASH

VIEW

Fibrosis Models in Mice and Rats

Selecting preclinical in vivo models that are reflective of clinical outcome is a key challenge in the development of new therapies to treat fibrotic diseases.  To accelerate research focused on pulmonary, renal, and liver fibrosis, WuXi AppTec has established a series of in vivo models supported with anti-fibrotic efficacy data.  Our platform also includes a …Read More >

Resource Type: Presentation
Resource Topic: Autoimmune and Inflammatory Diseases, Liver Diseases, NASH, Respiratory Diseases

VIEW

Translational Pharmacology of CNS and Metabolic Disorders for Testing New Modality Therapies

Animal studies may provide a close approximation to humans when addressing the key challenge of clinical translatability. In the preclinical setting, new insights into disease models and mechanisms are crucial to efficacy studies. In this webinar, Dr. Deming Xu, Chief Pharmacologist, Executive Director, and Head of In Vivo Pharmacology of WuXi AppTec Discovery Biology will …Read More >

Resource Type: Webinar
Resource Topic: Cardiovascular & Metabolic Diseases, Central Nervous System & Pain, in vivo Pharmacology, Metabolic Diseases, NASH, Oligonucleotides

VIEW

Case Study: Clinically Relevant NASH Animal Model

In this case study, we demonstrate clinical relevance of the HFD+CCL4 (high-fat diet and carbon tetrachloride) NASH animal model. Improvement of hepatic fibrosis has been a challenging endpoint in NASH clinical trials and selecting animal models that show anti-fibrotic efficacy has been equally challenging for the preclinical development of new NASH drugs.  Our findings indicate …Read More >

Resource Type: Case Study, Latest Science
Resource Topic: in vivo Pharmacology, Liver Diseases, Metabolic Diseases, NASH

VIEW

WuXi AppTec Discovery Services

Delivering comprehensive end-to-end solutions for creating, identifying, and supporting preclinical candidates, from discovery to development, with our integrated chemistry and biology research platforms.  

Resource Type: Brochure
Resource Topic: Antibodies, Antibody Drug Conjugate, Autoimmune and Inflammatory Diseases, Biochemical Assays, Biomarkers, Biophysical Assays, Candidate Selection, CAR-T Cell, Cardiovascular & Metabolic Diseases, Cell Therapies, Cell-based Assays, Cells and Protein Science, Central Nervous System & Pain, Chemical Biology and Proteomics, Dermatology, Discovery Chemistry, DNA-Encoded Library (DEL), DRUG DISCOVERY AND INNOVATION, Fragment-Based Drug Discovery, Gene Therapies, High-throughput screening (HTS), Hit Finding, Hit-to-Lead, Immunology, in silico services, in vitro biology, in vivo Pharmacology, in vivo Toxicology, Infectious Diseases, Lead Optimization, Liver Diseases, Mass Spectrometry-based Assays, Metabolic Diseases, NASH, Oligonucleotides, Oncology, Oncolytic Viruses, Ophthalmology, Phenotypic Assays, Quantum Mechanics, Rare Diseases, Respiratory Diseases, Safety and Early Toxicity, Screening Libraries, Screening Services, Small Molecules, Structural Biology, Target Identification and Validation, Target-Specific Assays, Targeted Protein Degradation, TECHNOLOGY PLATFORMS, THERAPEUTIC AREAS, THERAPEUTIC MODALITIES, Tumor Models

VIEW

NASH Animal Models and their Clinical Relevance – Quantitative Histopathology of Hepatic Fibrosis

Resource Type: Webinar
Resource Topic: Biomarkers, Lead Optimization, Liver Diseases, Metabolic Diseases, NASH

VIEW

Quantitative Histopathology of Fibrosis in an Animal Model of NASH

The hepatic fibrosis has been the most challenging aspect in the animal models for nonalcoholic steatohepatitis (NASH). Although it could induced by nutritional (high-fat died with high cholesterol, methionine and choline deficient diet, etc), chemical (carbon tetrachloride, thioacetamide, α-naphthylisothiocyanate etc.), and surgical (bile duct ligation) means, the clinical relevance of the resulting fibrosis remains an …Read More >

Resource Type: Article, Blog
Resource Topic: Biomarkers, Candidate Selection, Liver Diseases, Metabolic Diseases, NASH

VIEW


Resource Topics
× peptide, amino acid

Contact An Expert Today!